Literature DB >> 31930046

Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment.

Ning Pu1,2, Qiangda Chen1, Shanshan Gao2,3, Gao Liu4, Yayun Zhu2,4, Lingdi Yin2,5, Haijie Hu2,6, Li Wei4, Yong Wu2,7, Shimpei Maeda2,8, Wenhui Lou1, Jun Yu2, Wenchuan Wu1.   

Abstract

BACKGROUND: The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismally poor and is widely considered as an intricate genetic disorder. The mutational landscape of PDAC may directly reflect cancer immunogenicity and dictate the extent and phenotype of immune cell infiltration. In adverse, the microenvironment may also effect the gene expression of cancer cells, which is associated with clinical prognosis. Thus, it is crucial to identify genomic alterations in PDAC microenvironment and its impacts on clinical prognosis.
METHODS: The gene expression profiles, mutation data and clinical information of 179 pancreatic cancer patients with an initial pathologic diagnosis ranging from 2001 to 2013 were retrieved from The Cancer Genome Atlas (TCGA) database. The MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm for calculating immune scores and stromal scores and Tumor IMmune Estimation Resource (TIMER) resource for cell infiltrations were applied in this study.
RESULTS: The average immune score or stromal score of PDAC subtype was significantly higher than that of other specific subtypes. KRAS mutant cases had significantly lower immune scores (P=0.001) and stromal scores (P=0.007), in concert with lower immune scores in TP53 mutant cases (P=0.030). However, no significant difference was found in SMAD4 and CDKN2A mutations. In the cohort OS/RFS, the infiltration levels of CD8+ T cells, B cells, Macrophages, Neutrophils and DCs in high stromal score group were higher than those in the low score group (all P<0.001), as well as in immune score groups except for Macrophages in the cohort RFS. In the cohort OS/RFS, 317/379 upregulated genes and 9/6 downregulated genes were observed in the high immune score group, while 227/205 upregulated genes and 17/6 downregulated genes in the high stromal score group. With the analysis for prognostic value of DEGs, 82 and 58 DEGs respectively in the high immune and stromal score group were verified to be significantly associated with better OS (P<0.05), while 53 and 17 DEGs respectively with longer RFS (P<0.05). Functional enrichment analysis showed genes of prognostic values were significantly related to immune response.
CONCLUSIONS: A list of genes with prognostic value in PDAC microenvironment were obtained from functional enrichment analysis based on immune and stromal scores, which indicates a series of potential auxiliary prognostic biomarkers for PDAC are available. Further research on these genes may be valuable and helpful to understand the crosstalk between tumor and microenvironment, new immune evasion mechanisms and underlying novel therapeutic targets in an integrated manner. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Pancreatic ductal adenocarcinoma (PDAC); The Cancer Genome Atlas (TCGA); immune score; microenvironment; prognosis; stromal score

Year:  2019        PMID: 31930046      PMCID: PMC6944582          DOI: 10.21037/atm.2019.10.91

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  54 in total

1.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

2.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Authors:  Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

3.  Genomic hallmarks of localized, non-indolent prostate cancer.

Authors:  Michael Fraser; Veronica Y Sabelnykova; Takafumi N Yamaguchi; Lawrence E Heisler; Julie Livingstone; Vincent Huang; Yu-Jia Shiah; Fouad Yousif; Xihui Lin; Andre P Masella; Natalie S Fox; Michael Xie; Stephenie D Prokopec; Alejandro Berlin; Emilie Lalonde; Musaddeque Ahmed; Dominique Trudel; Xuemei Luo; Timothy A Beck; Alice Meng; Junyan Zhang; Alister D'Costa; Robert E Denroche; Haiying Kong; Shadrielle Melijah G Espiritu; Melvin L K Chua; Ada Wong; Taryne Chong; Michelle Sam; Jeremy Johns; Lee Timms; Nicholas B Buchner; Michèle Orain; Valérie Picard; Helène Hovington; Alexander Murison; Ken Kron; Nicholas J Harding; Christine P'ng; Kathleen E Houlahan; Kenneth C Chu; Bryan Lo; Francis Nguyen; Constance H Li; Ren X Sun; Richard de Borja; Christopher I Cooper; Julia F Hopkins; Shaylan K Govind; Clement Fung; Daryl Waggott; Jeffrey Green; Syed Haider; Michelle A Chan-Seng-Yue; Esther Jung; Zhiyuan Wang; Alain Bergeron; Alan Dal Pra; Louis Lacombe; Colin C Collins; Cenk Sahinalp; Mathieu Lupien; Neil E Fleshner; Housheng H He; Yves Fradet; Bernard Tetu; Theodorus van der Kwast; John D McPherson; Robert G Bristow; Paul C Boutros
Journal:  Nature       Date:  2017-01-09       Impact factor: 49.962

4.  Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Ujjwal Mukund Mahajan; Eno Langhoff; Elisabetta Goni; Eithne Costello; William Greenhalf; Christopher Halloran; Steffen Ormanns; Stephan Kruger; Stefan Boeck; Silvia Ribback; Georg Beyer; Frank Dombroswki; Frank-Ulrich Weiss; John P Neoptolemos; Jens Werner; Jan G D'Haese; Alexandr Bazhin; Julian Peterhansl; Svenja Pichlmeier; Markus W Büchler; Jörg Kleeff; Paula Ganeh; Matthias Sendler; Daniel H Palmer; Thomas Kohlmann; Roland Rad; Ivonne Regel; Markus M Lerch; Julia Mayerle
Journal:  Gastroenterology       Date:  2018-08-06       Impact factor: 22.682

Review 5.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

6.  Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer.

Authors:  Toru Nakanishi; Kazuyoshi Imaizumi; Yoshinori Hasegawa; Tsutomu Kawabe; Naozumi Hashimoto; Masakazu Okamoto; Kaoru Shimokata
Journal:  Cancer Immunol Immunother       Date:  2006-02-02       Impact factor: 6.968

Review 7.  Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression.

Authors:  Sadiye Amcaoglu Rieder; Ashok Chauhan; Ugra Singh; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Immunobiology       Date:  2009-05-20       Impact factor: 3.144

8.  A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.

Authors:  Martin C Abba; Ting Gong; Yue Lu; Jaeho Lee; Yi Zhong; Ezequiel Lacunza; Matias Butti; Yoko Takata; Sally Gaddis; Jianjun Shen; Marcos R Estecio; Aysegul A Sahin; C Marcelo Aldaz
Journal:  Cancer Res       Date:  2015-08-06       Impact factor: 12.701

9.  STRING v10: protein-protein interaction networks, integrated over the tree of life.

Authors:  Damian Szklarczyk; Andrea Franceschini; Stefan Wyder; Kristoffer Forslund; Davide Heller; Jaime Huerta-Cepas; Milan Simonovic; Alexander Roth; Alberto Santos; Kalliopi P Tsafou; Michael Kuhn; Peer Bork; Lars J Jensen; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2014-10-28       Impact factor: 16.971

10.  Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes.

Authors:  Ning Pu; Guochao Zhao; Shanshan Gao; Yutong Cui; Yadong Xu; Yang Lv; Abulimiti Nuerxiati; Wenchuan Wu
Journal:  Cent Eur J Immunol       Date:  2018-06-30       Impact factor: 2.085

View more
  10 in total

1.  TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma.

Authors:  Joanne Lundy; Linden J Gearing; Hugh Gao; Alison C West; Louise McLeod; Virginie Deswaerte; Liang Yu; Sean Porazinski; Marina Pajic; Paul J Hertzog; Daniel Croagh; Brendan J Jenkins
Journal:  Oncogene       Date:  2021-08-16       Impact factor: 9.867

Review 2.  Targeting KRAS in pancreatic cancer: new drugs on the horizon.

Authors:  Sahar F Bannoura; Md Hafiz Uddin; Misako Nagasaka; Farzeen Fazili; Mohammed Najeeb Al-Hallak; Philip A Philip; Bassel El-Rayes; Asfar S Azmi
Journal:  Cancer Metastasis Rev       Date:  2021-09-09       Impact factor: 9.237

3.  Prognostic value of biomarkers in the tumor microenvironment of pancreatic ductal adenocarcinoma.

Authors:  Nitish K Mishra; Siddesh Southekal; Chittibabu Guda
Journal:  Ann Transl Med       Date:  2020-05

4.  In Silico analyses of host immunity and stroma provide prognostic factors in early stage pancreatic ductal adenocarcinoma (PDAC).

Authors:  Madison H Williams; Daruka Mahadevan
Journal:  Ann Transl Med       Date:  2020-03

5.  Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.

Authors:  Weijia Wang; Liang Yan; Xiaoya Guan; Bin Dong; Min Zhao; Jianhui Wu; Xiuyun Tian; Chunyi Hao
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 6.244

6.  Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.

Authors:  Stephen L Abrams; Przemysław Duda; Shaw M Akula; Linda S Steelman; Matilde L Follo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Giuseppe Montalto; Maria Rita Emma; Melchiorre Cervello; Dariusz Rakus; Agnieszka Gizak; James A McCubrey
Journal:  Cells       Date:  2022-02-24       Impact factor: 7.666

7.  APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.

Authors:  James Andrew McCubrey; Stephen L Abrams; Linda S Steelman; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Paolo Lombardi; Agnieszka Gizak; Przemysław Duda
Journal:  Biomolecules       Date:  2022-02-08

8.  Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis.

Authors:  Jun Wang; Feng-Ting Dao; Lu Yang; Ya-Zhen Qin
Journal:  Sci Rep       Date:  2020-11-04       Impact factor: 4.379

9.  Microenvironment-related prognostic genes in esophageal cancer.

Authors:  Min-Hang Zhou; Xin-Kun Wang
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

10.  Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer.

Authors:  Shaojie Chen; Feifei Huang; Shangxiang Chen; Yinting Chen; Jiajia Li; Yaqing Li; Guoda Lian; Kaihong Huang
Journal:  Front Genet       Date:  2021-06-30       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.